A Study to Evaluate the Effect of Severe Renal Impairment on the Single-dose Pharmacokinetics of Odalasvir
PHASE1CompletedINTERVENTIONAL
Enrollment
16
Participants
Timeline
Start Date
November 9, 2016
Primary Completion Date
April 9, 2018
Study Completion Date
April 9, 2018
Conditions
Renal Insufficiency
Interventions
DRUG
Odalasvir
Participants will receive odalasvir 25 mg tablet, orally.
Trial Locations (2)
Unknown
Orlando
Knoxville
All Listed Sponsors
lead
Janssen Research & Development, LLC
INDUSTRY
NCT02961660 - A Study to Evaluate the Effect of Severe Renal Impairment on the Single-dose Pharmacokinetics of Odalasvir | Biotech Hunter | Biotech Hunter